We therefore aimed to characterize the effects of previously untested combinatorial approaches in B-ALL with KMT2A translocation involving the BCL-2 inhibitor VEN and the two PI3K inhibitors BKM-120 (BKM) and idelalisib (IDEL), as well as the AKT inhibitors MK-2206 (MK) and perifosine (PERI). This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.